18 results about "Bronchus" patented technology

The invention relates to the field of medical image processing, in particular to a pulmonary nodule natural orifice optimal path intelligent planning system which comprises a data preprocessing module, a bronchus three-dimensional segmentation module, a pulmonary nodule segmentation module, a differential geometric path search module, a path evaluation module and a doctor interaction module. The differential geometric path search module comprises a Riemannian curvature flow modeling unit, a multi-scale Gaussian curvature constraint unit and a geodesic curvature self-adaptive correction unit, can model bronchus into a Riemannian manifold, applies curvature flow optimization, and combines a multi-scale decomposition strategy and a geodesic theory to obtain a geodesic curvature self-adaptive correction model; precise description and optimal path planning of bronchial geometrical characteristics are realized, the path evaluation module provides multi-dimensional evaluation of blood vessel avoidance, diameter adaptation and curvature safety, and the doctor interaction module supports three-dimensional visualization and real-time path editing. The problem that a traditional Euclidean space algorithm is insufficient in description of complex forms of bronchus is solved by introducing a differential geometry theory.

The invention discloses a broncholung lavage fluid composition for treating non-small cell lung cancer, and relates to the technical field of cancer treatment. The preparation method of the bronchus lung lavage fluid composition for treating the non-small cell lung cancer comprises the following steps: S1, performing metagenome sequencing on a BALF sample, S2, grouping by R / NR based on differential strains obtained in S1 to obtain core bacteria, performing single-strain Kaplan-Meier survival analysis on the strains, and determining the survival rate of the single-strain Kaplan-Meier to obtain the bronchus lung lavage fluid composition for treating the non-small cell lung cancer. Finally, seven key microorganisms, namely bronchopulmonary lavage fluid combinations, which are remarkably related to immunotherapy PFS are locked; s3, determining the relationship between the seven key BALF bacteria and the existing immune therapeutic effect marker; and S4, verifying the generation conditions of IL6, IL8 and RANTES cytokines promoted by the seven strains through an in-vitro cell experiment, and revealing the activation and enhancement effects of the seven strains on immune cell functions. According to the invention, the immunotherapy effect of the non-small cell lung cancer patient can be promoted to be improved by combining a plurality of beneficial specific microorganisms in an airway administration mode. In conclusion, the method has a good application prospect.

The application provides a lung segment bronchus catheter, which comprises a catheter tail end ventilation and suction interface, a cuff inflation device, an outer tube, an inner tube, a front end cuff and a guide end formed by the inner tube; the cuff is annularly arranged on the outer surface of the catheter head, and is in the form of a ring ball wrapped around the inner tube in the inflated state; the cuff inflation interface and the cuff inflation conduit are communicated between the gap between the outer tube and the inner tube at the catheter tail and lead to the cuff; the catheter ventilation and suction interface is communicated with the inner tube and the guide end formed by the inner tube, and a guide wire is arranged in the catheter ventilation and suction interface to form a straight lumen. The catheter can enter the target lung segment or sub-lung segment bronchus through the operation channel of the bronchoscope, the inflated cuff seals the airway cavity around the lung segment bronchus catheter cavity, then the guide wire is pulled out from the lung segment bronchus catheter cavity, the target lung segment or sub-lung segment is inflated through the catheter ventilation and suction interface, so that the anatomical range of the target lung segment or sub-lung segment after ventilation is revealed, the technical problem that a thoracic surgeon cannot accurately identify the anatomical range of the target lung segment in the operation is effectively solved, and the thoracic surgery anatomical partial lobectomy operation is facilitated.

The present disclosure provides methods, uses, and pharmaceutical compositions with utility in the treatment of acute lung injuries or chronic lung diseases including, bronchopulmonary dysplasia and exacerbations of bronchopulmonary dysplasia.

Described is a method for improving the condition of a patient suffering from Non-Cystic Fibrosis Bronchiectasis (NCFB), comprising administering to the patient by inhalation from 2.5 million international units (MIU) to 6 MIU of colistimethate sodium (CMS) once a day for a period of at least 28 days. Other embodiments are also disclosed.

The invention relates to the field of traditional Chinese medicines, in particular to novel application of a Sweeping Tianhu lung-clearing and cough-relieving composition in treatment of chronic obstructive pulmonary disease. Animal experiment studies show that the Sweetio lung-clearing and cough-relieving composition can significantly improve the lung function of COPD mice and inhibit bronchial abnormal remodeling. The action mechanism of the composition is related to inhibition of lung tissue cell apoptosis, alleviation of inflammatory cell infiltration and improvement of abnormal remodeling of bronchus, which indicates that the Sweeping Litu composition for clearing away lung-heat and relieving cough has obvious pharmacological activity of resisting COPD (chronic obstructive pulmonary disease).

The invention relates to medical uses of alvelestat, and pharmaceutically acceptable salts thereof, in the treatment of non-cystic fibrosis bronchiectasis.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to the field of biological medicine, in particular to a biomarker for diagnosing pneumonia. The invention provides application of a biomarker in preparation of a kit for diagnosing pneumonia and / or evaluating the curative effect of pneumonia, and is characterized in that the biomarker comprises ADA2 in bronchoalveolar lavage fluid, and the kit is used for quantitatively detecting the content of ADA2 in a bronchoalveolar lavage fluid sample of a subject. By detecting the content of ADA2 in a bronchoalveolar lavage fluid sample of a subject, whether the subject is a severe pneumonia patient or not can be quickly and accurately diagnosed.

Aspects of the present disclosure provide compositions comprising NEK10 for example, wild-type NEK10 or a hyperactive NEK10 mutant such as NEK10S684D, and methods of using such for treating a respiratory disorder such as bronchiectasis.

The utility model relates to a system for eliminating, reducing, clearing and sucking sputum and treating waste sputum. The system comprises a sputum tank, a liquid medicine tank and a liquid tank. The inner cavity of the tank is connected with a positive-negative pressure air source, a water source and a sputum suction and drainage pipe. The device further comprises a foot switch, an electromagnetic valve, a pressure regulator, a controller, an electromagnetic vibrator, an expiration electromagnetic valve switch, a trachea cannula, a double-channel sputum suction tube and the like. According to the principle, during sputum excretion, resonance is generated during lung expiration of a patient by controlling the switching frequency of the electromagnetic valve and vibration of the vibrator in a timing mode, lung secretions continuously overflow, and the treatment effects of sputum excretion, inflammation diminishing and detoxification are achieved. During sputum suction, the sputum suction tube is inserted into a trachea and a bronchus within more than ten seconds, and a trace amount of liquid is used for reducing and clearing sputum and synchronously sucking sputum, so that the ventilation and oxygen supply effects are improved, and the sputum suction tube plays a crucial role in rescuing the life of a critically ill patient. Sucked sticky sputum is added with water, stirred and discharged into a sewage station, replacement and destruction of a sputum suction bottle are omitted, cross infection is prevented, and environment-friendly biological safety scientific management is facilitated.

The invention provides an indoor pathogen aerosol transmission risk quantitative evaluation and closed-loop control method, and relates to the technical field of public health environment engineering.The indoor pathogen aerosol transmission risk quantitative evaluation and closed-loop control method comprises the steps that multi-dimensional environment parameters such as spatial layout, ventilation operation parameters, pathogen characteristics, personnel activity and protection equipment parameters are obtained; obtaining an air concentration distribution field and a surface concentration distribution field through numerical calculation; respectively constructing dose calculation and dose response models of the contact path and the inhalation path, wherein the inhalation path divides the respiratory tract into at least an upper respiratory tract region, a tracheal bronchus region and a pulmonary alveolar region, and calculating a partitioned deposited dose; monte Carlo simulation is adopted to represent the randomness of key parameters, the contact infection probability, the inhalation infection probability and the comprehensive infection risk are output, a ventilation control set value or a control instruction meeting a risk threshold value is generated, and accurate evaluation and closed-loop control of the indoor pathogen aerosol transmission risk can be achieved.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.

The utility model relates to a kind of bronchus blocking catheter of anti-displacement blockage, the top end of the blocking catheter movably connects with the fixed strip for sealing and tightening cover tight component to blocking catheter;The clamping device includes the clamping component for clamping and fixing bronchus in cover tight device, and the driving component for driving two clamping components to move in opposite directions is arranged in cover tight device. By cover cap insertion to the top end of blocking catheter, then by two rotating fixed strip is clamped in clamping strip, cover cap can be covered and tightened, three elastic strips can be used to clamp and fix bronchus, then by hand wheel driving bidirectional screw rod is rotated, two threaded sleeve plates can be made along the two threaded portions on the rod body of bidirectional screw rod to bronchus close, while fixed sleeve plate can move along guide rod, and bronchus is clamped and fixed, to prevent bronchus from the risk of loosening and falling.

The invention discloses an application of a red grass snore-ceasing traditional Chinese medicine composition in preparation of a medicine for treating chronic obstructive pulmonary disease. Specifically, the red grass snore-relieving traditional Chinese medicine composition can improve the lung function of a patient suffering from the chronic obstructive pulmonary disease in a dose-dependent manner, improve lung injury of the patient suffering from the chronic obstructive pulmonary disease, reduce the levels of IL-1beta, IL-6 and TNF-alpha inflammatory factors in serum, alveolar bronchial lavage fluid (BALF) and lung tissue of the patient suffering from the chronic obstructive pulmonary disease, and improve the snore-relieving effect of the patient suffering from the chronic obstructive pulmonary disease. The inflammation level of a patient with the chronic obstructive pulmonary disease is improved.

The invention relates to the technical field of machine reinforcement learning, in particular to a bronchiectasis recognition method based on reinforcement learning, and the method comprises the steps: obtaining a suspected region of a CT image through segmentation; based on the tangent relation between the artery and the bronchus, analyzing the solid expression of the artery in the CT image and the cavity expression of the bronchus in the CT image, and obtaining an artery-like area and a suspected bronchus edge in the suspected area in the CT image; acquiring a plurality of bronchus-artery areas in each CT image according to the boundary arc expression of the suspected bronchus edge and the regular circle state of the artery-like area; according to the overlapping condition of the bronchial-artery region in other CT images, obtaining a repair index of each pixel point; and performing bronchiectasis identification based on reinforcement learning according to the repair index. The invention aims to eliminate artifacts of bronchus caused by respiration in the CT image and improve the accuracy of bronchiectasis recognition based on reinforcement learning.